Allurion and GLP-1: Optimizing Muscle During Weight Loss Therapy
Allurion Technologies plans to launch a clinical study combining its weight-loss program with GLP-1 agonists to address muscle loss,...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Allurion Technologies plans to launch a clinical study combining its weight-loss program with GLP-1 agonists to address muscle loss,...
A Massachusetts General Hospital (MGH) study assessed the real-world impact of binx health’s point-of-care (POC) testing for chlamydia and...
Neuvivo announced promising results from a new analysis of its investigational immunotherapy NP001 for Amyotrophic Lateral Sclerosis (ALS). The...
Medidata, a Dassault Systèmes company, and Tigermed, a global clinical research provider, extended their 13-year partnership. This renewed collaboration...
Astria Therapeutics has launched a Phase 1a clinical trial for STAR-0310, a monoclonal antibody designed to treat atopic dermatitis...
Pluri Inc. secured a $6.5 million private investment from Alejandro Weinstein, who will join the company’s board. Simultaneously, Pluri...
Tiziana Life Sciences announced positive preclinical results for their intranasal anti-CD3 monoclonal antibody, foralumab, in treating traumatic spinal cord...
MiNK Therapeutics announced a presentation at the ASCO GI Symposium detailing a Phase 2 trial of its iNKT cell...
Outlook Therapeutics presented 12-week data from its NORSE EIGHT clinical trial of ONS-5010 (bevacizumab-vikg) for wet age-related macular degeneration...
AIM ImmunoTech Inc. announced final clinical study results (AMP-518) for Ampligen in treating post-COVID conditions, specifically fatigue. The study,...